Mutations and Nuclear Accumulation of Beta-catenin Correlate with Intestinal Phenotypic Expression in Human Gastric Cancer
Overview
Pathology
Affiliations
Aims: Abnormal localization of beta-catenin is frequently observed in human gastric cancers. The aim of the present study was to evaluate relationships among gastrointestinal differentiation phenotypes, beta-catenin localization and mutations of Wnt signalling genes.
Methods And Results: Seventy-seven regions in 39 gastric adenocarcinomas were classified according to beta-catenin localization and gastric and intestinal phenotypes. Cases with membranous beta-catenin localization showed a gradual decrease from gastric (G) (55% = 6/11) and gastric-and-intestinal-mixed (GI) (17% = 5/29) to intestinal (I) (0% = 0/21) phenotypes, while those with nuclear localization showed a concomitant increase: 18% (2/11), 41% (12/29), 95% (20/21) and 63% (10/16) for G, GI, I and null type (N), respectively (P < 0.001, membranous versus nuclear localization in G, GI through I). Mutations in exon 3 of the beta-catenin gene were found in G (50% = 1/2), GI (67% = 8/12), I (45% = 9/20) and N (0% = 0/10) regions with nuclear beta-catenin localization (GI versus N, P < 0.01; I versus N, P < 0.05). Adenomatous polyposis coli (APC) gene mutations were demonstrated only in GI, I and N types, irrespective of beta-catenin localization. Molecular analysis of these genes revealed 10 tumours to be heterogeneous out of 16 informative cases (62.5%).
Conclusion: Intestinal phenotypic expression is accompanied by a shift from membranous to cytoplasmic/nuclear accumulation of beta-catenin. In contrast, N-type regions may progress along a different pathway.
Zhang X, Chen Y, Yao M, Xiong R, Liu B, Zhu X Sci Rep. 2024; 14(1):13127.
PMID: 38849404 PMC: 11161650. DOI: 10.1038/s41598-024-63812-3.
Taghavi S, Ghorbani M, Panahi M, Nazem S, Karimi M, Salimi V Mol Biol Rep. 2023; 50(8):6425-6434.
PMID: 37326745 DOI: 10.1007/s11033-023-08523-0.
Khademian N, Mirzaei A, Hosseini A, Zare L, Nazem S, Babaheidarian P Sci Rep. 2022; 12(1):9488.
PMID: 35676319 PMC: 9177768. DOI: 10.1038/s41598-022-13685-1.
Wnt/β-catenin signaling in cancers and targeted therapies.
Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L Signal Transduct Target Ther. 2021; 6(1):307.
PMID: 34456337 PMC: 8403677. DOI: 10.1038/s41392-021-00701-5.
Gardrat S, Houy A, Brooks K, Cassoux N, Barnhill R, Dayot S Cancers (Basel). 2021; 13(15).
PMID: 34359736 PMC: 8345091. DOI: 10.3390/cancers13153836.